What AbbVie's Recent Drug News Means for Shareholders
At the end of last month, AbbVie (NYSE: ABBV) informed shareholders that it had submitted its application for Skyrizi to the European Medicines Agency (EMA) to treat patients aged 16 and older diagnosed with moderate to severe Crohn's disease.
But if Crohn's is approved as a third indication for the drug in the European Union, what is Skyrizi's sales potential in that market? To answer that question, let's go over the phase 3 clinical trial results and assess the addressable market.
Image source: Getty Images.
Source Fool.com
